18 June 2013
Keywords: merck, kgaa, erbitux, gets, nice, ok, subset
Article | 30 June 2008
The National Institute for Health and Clinical Excellence (NICE) has recommended Merck KGaA's Erbitux (cetuximab) in combination with
radiotherapy for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 June 2008
17 June 2013
© 2013 thepharmaletter.com